Portal de Periódicos da CAPES

Incidence of chronic Philadelphia chromosome negative (Ph−) myeloproliferative disorders in the Côte d'Or area, France, during 1980–99

2005; Wiley; Volume: 258; Issue: 1 Linguagem: Inglês

10.1111/j.1365-2796.2005.01505.x

1365-2796

François Girodon, Valérie Jooste, Marc Maynadié, Bernardine Favre, Céline Schaeffer, P Carli,

Chronic Myeloid Leukemia Treatments

Dear Sir, We read with interest the recent article of Johansson et al. [1] which described the incidence rates for chronic Philadelphia chromosome negative (Ph−) myeloproliferative disorders (MPD) in the city of Göteborg. Their results showed an increased incidence for essential thrombocythemia (ET), especially for males, whereas no significant modification was noted in the incidence of polycythemia vera (PV) nor idiopathic myelofibrosis (IMF). Interestingly, the size of the population of the Côte d'Or area is similar than the one of the city of Göteborg (473 651 and 506 755 inhabitants in Côte d'Or in 1982 and 1999 respectively; 424 085 and 462 470 in Göteborg in 1983 and 1999 respectively) and this allows comparisons between two European regions. We previously reported the epidemiologic features of PV in a population-based registry between 1980 and 1990 [2]. The overall age-standardized incidence rate, based on the world population was 0.7, close to those frequently reported [3]. We analysed the incidence of Ph− MPD between 1991 and 1999, then we measured the evolution of incidence between the two periods. A total of 301 MPD were registered for the period from 1980 to 1999, including 86 PV, 156 ET and 59 IMF (Table 1). In order to compare our results with those of Johansson, we calculated the incidence based on the European Standard Population, and not on the World Population. In our registry, the incidence of PV in the 1991–99 period was similar to the one observed in the 1980–90 period; no difference between genders was noted. When compared with the results obtained by Johansson et al., the incidence of PV is much lower in Côte d'Or than the one observed in Göteborg (0.84 vs. 1.97 per 105 inhabitants). It is important to note that the incidence of PV reported in Göteborg is one of the highest published [4]. On the contrary, the incidence rate of ET in our registry was similar to the one described by Johansson et al. (1.43 and 1.55 per 105 inhabitants respectively). We also observed a significant increase in the incidence of ET (P =0.001) for men and women. No change during time was noted for IMF. One explanation of the increased rate of ET is a wider availability of platelet counts in routine examination, and we agree with Johansson's comments. In conclusion, compared with Johansson's results, our population-based registered data revealed a lower rate in the incidence of PV but confirmed the increase of incidence of ET over the time period. No conflict of interest was declared.